BlackRock Advisors LLC boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 326,200 shares of the specialty pharmaceutical company’s stock after buying an additional 6,012 shares during the period. BlackRock Advisors LLC owned about 0.54% of Jazz Pharmaceuticals PLC worth $46,095,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Albion Financial Group UT boosted its stake in Jazz Pharmaceuticals PLC by 0.5% in the second quarter. Albion Financial Group UT now owns 2,783 shares of the specialty pharmaceutical company’s stock valued at $393,000 after buying an additional 15 shares during the last quarter. OLD National Bancorp IN boosted its stake in Jazz Pharmaceuticals PLC by 1.5% in the second quarter. OLD National Bancorp IN now owns 1,949 shares of the specialty pharmaceutical company’s stock valued at $275,000 after buying an additional 29 shares during the last quarter. Independent Portfolio Consultants Inc. boosted its stake in Jazz Pharmaceuticals PLC by 2.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 2,235 shares of the specialty pharmaceutical company’s stock valued at $292,000 after buying an additional 50 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in Jazz Pharmaceuticals PLC by 0.4% in the first quarter. Loomis Sayles & Co. L P now owns 13,839 shares of the specialty pharmaceutical company’s stock valued at $1,807,000 after buying an additional 50 shares during the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD boosted its stake in Jazz Pharmaceuticals PLC by 2.0% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 4,275 shares of the specialty pharmaceutical company’s stock valued at $604,000 after buying an additional 82 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 126.04 on Monday. The stock’s 50 day moving average price is $135.28 and its 200-day moving average price is $139.68. The stock has a market cap of $7.63 billion, a price-to-earnings ratio of 22.16 and a beta of 0.93. Jazz Pharmaceuticals PLC has a 52-week low of $108.50 and a 52-week high of $165.15.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.80 by $0.17. Jazz Pharmaceuticals PLC had a return on equity of 28.39% and a net margin of 25.46%. The business had revenue of $381 million for the quarter, compared to analysts’ expectations of $376.40 million. During the same period last year, the business earned $2.41 earnings per share. The company’s revenue for the quarter was up 14.2% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals PLC will post $10.08 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on the company. Wells Fargo & Co. reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Saturday, June 18th. SunTrust Banks Inc. restated a “buy” rating and set a $210.00 target price (up from $200.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, June 2nd. Piper Jaffray Cos. restated a “buy” rating and set a $186.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, May 31st. Goldman Sachs Group Inc. began coverage on Jazz Pharmaceuticals PLC in a report on Monday, June 6th. They set a “buy” rating and a $196.00 target price on the stock. Finally, Deutsche Bank AG restated a “buy” rating and set a $158.00 target price (up from $155.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company. Jazz Pharmaceuticals PLC has an average rating of “Buy” and an average price target of $185.67.

In related news, Director Seamus Mulligan sold 27,968 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $128.32, for a total transaction of $3,588,853.76. Following the sale, the director now owns 1,072,411 shares in the company, valued at $137,611,779.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $150.00, for a total transaction of $150,000.00. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.